Here are the Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Cyp1a2 gene mutation and smoking, cyp2d6 genetic variation on medication, https //www pharmvar org/gene/cyp2c19, what are the sources of genetic variation, what causes genetic variation, define genetic variation, what does cyp2c19 do, cyp1a2 gene mutation and smoking, cyp2c9 phenotype normal metabolizer, medications metabolized by cyp2c9.
Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors
Background: The major enzyme that is responsible for Sulfonylureas (SUs) metabolism is hepatic cytochrome P-450 2C9 (CYP2C9). It is encoded by the polymorphic gene CYP2C9, which has many allelic variants, among those the CYP2C9*2 and CYP2C9*3 are the most common and clinically significant allelic variations. People with diabetes mellitus type 2 (T2DM) are more likely to develop cardiovascular disease (CVD), and their risk of dying from it is more than two times higher than that of people without the condition. The purpose of this study was to evaluate the association of genetic variations in the CYP2C9 gene with cardiovascular risk factors by investigating CYP2C9*1, *2, *3, *5, *11, and *13 allelic variants. Methods and
results: A total of 226 participants were enrolled in the current case-control study. Allele-specific amplification- PCR (ASA-PCR) was used to determine the allele of different variations and the results were con firmed by sequencing. The findings of this study showed the presence of the CYP2C9*2 allele in the T2DM group does not differ from its percentage in the control group. Also, CYP2C9*3 allele frequencies identified by Hardy-Weinberg equilibrium (HWE) analysis law were not significant, p = 0.6593 and 0.5828 in T2DM and control groups. There is no statistically significant difference between the control and diabetes groups involving the distribution of CYP2C9 alleles and CYP2C9*5, *11, and *13 polymorphisms were absent in the Iraqi population. No carrier for the CYP2C9*3 homozygous state was found in both groups. Conclusions: According to these results T2DM patients with the CYP2C9*2 and *3 variants have an increased risk of developing hypertension. © 2024, The Author(s), under exclusive licence to Springer Nature B.V.
Authors : Rasool G.S.; Al-Awadi S.J.; Hussien A.A.; Al-Attar M.M.
Source : Springer Science and Business Media B.V.
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1007/s11033-023-09151-4 |
| ISSN | 03014851 |
| Volume | 51 |
You can download the article here
If You have any problem, contact us here